Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

@article{Lockhart2009SafetyAT,
  title={Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.},
  author={Ian A Lockhart and Sarah A Mitchell and Suzannah Kelly},
  journal={Dementia and geriatric cognitive disorders},
  year={2009},
  volume={28 5},
  pages={389-403}
}
BACKGROUND/AIMS The purpose of this systematic review was to compare the safety and tolerability of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine for treating mild to moderate Alzheimer's disease (AD) patients in routine clinical practice. METHODS Electronic databases (Cochrane Library, Medline, EMBASE; accessed October 2008) and manual bibliographic searches were conducted to identify head-to-head non-randomised studies examining ChEIs for the treatment of AD… CONTINUE READING